Biological products, like therapeutic antibodies, are highly complex drugs that require both careful manufacturing and testing to ensure product quality and consistency.
This study investigates Mosunetuzumab-axgb, a bispecific CD20-directed CD3 T cell engaging antibody (BsAb), approved by the FDA for refractory follicular lymphoma.
Charge variants between Mosunetuzumab-axgb (Lunsumio) and a biosimilar were compared, using MauriceFlex for separation and IdeS (FabRICATOR®) for subunit-level mass spectrometry analysis.
Download this poster, presented at the 16th Annual Bioprocessing Summit, to see the data and discover streamlined approach to charge variant fractionation and LC-MS analysis.
